Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2.
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Aliskiren (Primary) ; Angiotensin receptor antagonists
- Indications Essential hypertension
- Focus Pharmacodynamics
- Acronyms SMART-2
- 10 Jun 2017 Biomarkers information updated
- 27 Feb 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 03 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.